Published: Aug. 2, 2023
Language: Английский
Published: Aug. 2, 2023
Language: Английский
Virology Journal, Journal Year: 2023, Volume and Issue: 20(1)
Published: Nov. 15, 2023
Abstract Background Omicron's high transmissibility and variability present new difficulties for COVID-19 vaccination prevention therapy. In this article, we analyzed the sensitivity of vaccine-induced antibodies as well effect booster vaccinations against Omicron sublineages. Methods We looked Randomized Controlled Trials cohort studies that reported vaccines sublineages up to 28 July 2022 through PubMed, Cochrane Library, EMBASE, Web Science. Quantitative synthesis was carried out using Stata 16.0 RevMa5.3, then serum NT50 antibody neutralize were assessed before after vaccination. This study registered with PROSPERO number CRD42022350477. Results meta-analysis included 2138 patients from 20 studies, showed a significant difference compared 2 dosage: BA.1/BA.1.1 (SMD = 0.80, 95% CI: 0.75–0.85, P 0.00), BA.2/BA.2.12.1 0.77, 0.69–0.85, BA.3 0.91, 0.83–1.0, BA.4/5 0.60–0.94, 0.00). The vaccines-induced decreased by at least 5-folds vaccination, particularly in case which had most notable decline vaccine effectiveness. Conclusion After neutralization ability increased, but susceptibility control virus, may be clue future prevention.
Language: Английский
Citations
1bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2023, Volume and Issue: unknown
Published: Aug. 14, 2023
SUMMARY A series of SARS-CoV-2 variants emerged during the pandemic under selection for neutralization resistance. Convalescent and vaccinated sera show consistently different cross-neutralization profiles depending on infecting or vaccine variants. To understand basis this heterogeneity, we modeled serum titers 165 after infection vaccination with historically prominent lineages tested against 18 variant pseudoviruses. Cross-neutralization were well captured by models incorporating autologous neutralizing combinations specific shared differing mutations between infecting/vaccine Infecting/vaccine variant-specific identified that significantly impacted quantified their relative contributions. Unified explained across all provided accurate predictions holdout data comprising untested as variants, test Finally, comparative modeling 2-dose versus 3-dose mRNA-1273 revealed third dose overcame key resistance to improve breadth. HIGHLIGHTS Modeled using at sites Identified impact Accurately predicted convalescent/vaccine Showed overcomes
Language: Английский
Citations
0Human Vaccines & Immunotherapeutics, Journal Year: 2023, Volume and Issue: 19(3)
Published: Nov. 28, 2023
Heterologous vaccination with inactivated vaccine followed by adenoviral vector-based has shown superiority in enhancing immune response compared to homologous primary series. However, data comparing immunity decline after a third booster following heterologous CoronaVac/ChAdOx-1nCov-19 been limited. Here, we assessed neutralizing activity against omicron variant and T cell at 3 months monitoring 96 individuals who received ChAdOx-1nCov-19, BNT162b2, or mRNA-1273 as dose CoronaVac/ChAdOx-1nCov-19. Comparing the antibody levels 1 month(s) booster, results showed persistence of anti-RBD IgG all regimens, level waning slower ChAdOx-1nCov-19 boosted group (geometric mean ratio (GMR): 0.64 (95%CI: 0.59–0.70)) BNT162b2 (0.34 (95%CI:0.31–0.38)) groups (0.32 0.29–0.36)). Neutralizing BA.2 BA.4/5 dropped 1.2 1.5-fold but remained detectable, highest observed group, groups, respectively. Furthermore, number reactivity decreased while it increased 3-month post-boost month. Data on durability could help comprehensively optimize strategy.
Language: Английский
Citations
0Published: Aug. 2, 2023
Language: Английский
Citations
0